Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.

Satheesan S, Li H, Burnett JC, Takahashi M, Li S, Wu SX, Synold TW, Rossi JJ, Zhou J.

J Virol. 2018 Mar 14;92(7). pii: e02118-17. doi: 10.1128/JVI.02118-17. Print 2018 Apr 1.

PMID:
29343582
2.

A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy.

Cho M, Gong J, Frankel P, Synold TW, Lim D, Chung V, Chao J, Li D, Chen Y, Sentovich S, Melstrom K, Singh G, Luevanos E, Fakih M.

Oncotarget. 2017 Jul 18;8(45):79750-79760. doi: 10.18632/oncotarget.19336. eCollection 2017 Oct 3.

3.

Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS.

Mol Ther Oncolytics. 2016 Dec 14;4:67-76. doi: 10.1016/j.omto.2016.11.004. eCollection 2017 Mar 17.

4.

Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.

Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D'Apuzzo M, Metz MZ, Najbauer J, Bedell V, Vo T, Gutova M, Frankel P, Chen M, Aboody KS.

Clin Cancer Res. 2017 Jun 15;23(12):2951-2960. doi: 10.1158/1078-0432.CCR-16-1518. Epub 2016 Dec 15.

PMID:
27979915
5.

Low Testosterone Alters the Activity of Mouse Prostate Stem Cells.

Zhou Y, Copeland B, Otto-Duessel M, He M, Markel S, Synold TW, Jones JO.

Prostate. 2017 Apr;77(5):530-541. doi: 10.1002/pros.23290. Epub 2016 Dec 14.

PMID:
27976414
6.

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.

Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN Jr.

Br J Haematol. 2018 Feb;180(3):445-448. doi: 10.1111/bjh.14333. Epub 2016 Sep 21. No abstract available.

PMID:
27650362
7.

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

Kirschbaum MH, Frankel P, Synold TW, Xie Z, Yen Y, Popplewell L, Chen R, Aljitawi O, Tuscano JM, Chan KK, Newman EM.

Leuk Lymphoma. 2016 Oct;57(10):2307-14. doi: 10.3109/10428194.2016.1146947. Epub 2016 Feb 19.

8.

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.

Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM.

Cancer Chemother Pharmacol. 2015 Nov;76(5):897-907. doi: 10.1007/s00280-015-2868-7. Epub 2015 Sep 11.

9.

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.

Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV.

Cancer Chemother Pharmacol. 2015 Mar;75(3):495-503. doi: 10.1007/s00280-014-2667-6. Epub 2015 Jan 4.

10.

Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age.

Hurria A, Blanchard MS, Synold TW, Mortimer J, Chung CT, Luu T, Katheria V, Rotter AJ, Wong C, Choi A, Feng T, Ramani R, Doan CM, Brown J, Somlo G.

Oncologist. 2015 Jan;20(1):37-44. doi: 10.1634/theoncologist.2014-0202. Epub 2014 Dec 9.

11.

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.

Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM.

Br J Cancer. 2014 Dec 9;111(12):2268-74. doi: 10.1038/bjc.2014.554. Epub 2014 Oct 28.

12.

Iron chelators induce autophagic cell death in multiple myeloma cells.

Pullarkat V, Meng Z, Donohue C, Yamamoto VN, Tomassetti S, Bhatia R, Krishnan A, Forman SJ, Synold TW.

Leuk Res. 2014 Aug;38(8):988-96. doi: 10.1016/j.leukres.2014.06.005. Epub 2014 Jun 17.

PMID:
24998390
13.

A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent.

Portnow J, Badie B, Liu X, Frankel P, Mi S, Chen M, Synold TW.

J Neurooncol. 2014 May;118(1):169-77. doi: 10.1007/s11060-014-1415-4. Epub 2014 Mar 15.

14.

Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.

Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, Tirughana R, Ghoda LY, Barish ME, Brown CE, Najbauer J, Potter PM, Portnow J, Synold TW, Aboody KS.

Stem Cells Transl Med. 2013 Dec;2(12):983-92. doi: 10.5966/sctm.2012-0177. Epub 2013 Oct 28.

15.

A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, Gaur S, Smith DL, Yuan YC, Synold TW, Horne D, Yen Y.

Cancer Res. 2013 Nov 1;73(21):6484-93. doi: 10.1158/0008-5472.CAN-13-1094. Epub 2013 Sep 26.

16.

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1089-96. doi: 10.1007/s00280-013-2297-4. Epub 2013 Sep 22.

17.

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.

Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM.

Cancer Chemother Pharmacol. 2013 Jul;72(1):85-91. doi: 10.1007/s00280-013-2171-4. Epub 2013 May 28.

18.

Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.

Aboody KS, Najbauer J, Metz MZ, D'Apuzzo M, Gutova M, Annala AJ, Synold TW, Couture LA, Blanchard S, Moats RA, Garcia E, Aramburo S, Valenzuela VV, Frank RT, Barish ME, Brown CE, Kim SU, Badie B, Portnow J.

Sci Transl Med. 2013 May 8;5(184):184ra59. doi: 10.1126/scitranslmed.3005365.

19.

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.

Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7.

20.

Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.

Gu L, Chen J, Synold TW, Forman BM, Kane SE.

J Pharmacol Exp Ther. 2013 Jun;345(3):438-45. doi: 10.1124/jpet.113.203562. Epub 2013 Mar 26.

21.

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.

Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CHJ, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y.

Invest New Drugs. 2013 Aug;31(4):986-1000. doi: 10.1007/s10637-012-9921-8. Epub 2013 Feb 9.

22.

A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.

Portnow J, Badie B, Markel S, Liu A, D'Apuzzo M, Frankel P, Jandial R, Synold TW.

Eur J Cancer. 2013 May;49(7):1634-40. doi: 10.1016/j.ejca.2013.01.001. Epub 2013 Feb 4.

23.

Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts.

Doroshow JH, Gaur S, Markel S, Lu J, van Balgooy J, Synold TW, Xi B, Wu X, Juhasz A.

Free Radic Biol Med. 2013 Apr;57:162-75. doi: 10.1016/j.freeradbiomed.2013.01.002. Epub 2013 Jan 11.

24.

Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice.

Synold TW, Xi B, Wu J, Yen Y, Li BC, Yang F, Phillips JW, Nickols NG, Dervan PB.

Cancer Chemother Pharmacol. 2012 Oct;70(4):617-25. Epub 2012 Aug 21.

25.

A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.

Venkatakrishnan K, Kramer WG, Synold TW, Goodman DB, Sides E 3rd, Oliva C.

Eur J Clin Pharmacol. 2012 Oct;68(10):1347-55. doi: 10.1007/s00228-012-1262-1. Epub 2012 Mar 30.

PMID:
22460239
26.

Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.

Gutova M, Shackleford GM, Khankaldyyan V, Herrmann KA, Shi XH, Mittelholtz K, Abramyants Y, Blanchard MS, Kim SU, Annala AJ, Najbauer J, Synold TW, D'Apuzzo M, Barish ME, Moats RA, Aboody KS.

Gene Ther. 2013 Feb;20(2):143-50. doi: 10.1038/gt.2012.12. Epub 2012 Mar 8.

27.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y.

Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22.

28.

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.

Portnow J, Frankel P, Koehler S, Twardowski P, Shibata S, Martel C, Morgan R, Cristea M, Chow W, Lim D, Chung V, Reckamp K, Leong L, Synold TW.

Cancer Chemother Pharmacol. 2012 Feb;69(2):505-14. doi: 10.1007/s00280-011-1721-x. Epub 2011 Aug 18.

29.

Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.

Stein AS, O'Donnell MR, Synold TW, Dagis AC, Tsirunyan A, Nademanee AP, Parker PM, Pullarkat VA, Snyder DS, Spielberger RT, Wong JY, Alvarnas JC, Thomas SH, Forman SJ.

Bone Marrow Transplant. 2011 Sep;46(9):1256-62. doi: 10.1038/bmt.2010.295. Epub 2010 Dec 13.

30.

Baicalin increases VEGF expression and angiogenesis by activating the ERR{alpha}/PGC-1{alpha} pathway.

Zhang K, Lu J, Mori T, Smith-Powell L, Synold TW, Chen S, Wen W.

Cardiovasc Res. 2011 Feb 1;89(2):426-35. doi: 10.1093/cvr/cvq296. Epub 2010 Sep 16.

31.

Atherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase.

Gao Q, Esworthy RS, Kim BW, Synold TW, Smith DD, Chu FF.

Inflamm Bowel Dis. 2010 Dec;16(12):2043-54. doi: 10.1002/ibd.21317.

32.

The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.

Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW.

Clin Cancer Res. 2009 Nov 15;15(22):7092-8. doi: 10.1158/1078-0432.CCR-09-1349. Epub 2009 Oct 27.

33.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1149-55. doi: 10.1007/s00280-009-0977-x. Epub 2009 Mar 26.

34.

A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging.

Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5394-9. doi: 10.1073/pnas.0807343106. Epub 2009 Mar 12.

35.

Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.

Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED.

Clin Genitourin Cancer. 2008 Sep;6(2):103-9. doi: 10.3816/CGC.2008.n.016.

PMID:
18824433
36.

A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).

Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L.

Invest New Drugs. 2008 Jun;26(3):265-72. doi: 10.1007/s10637-007-9103-2. Epub 2008 Jan 15.

PMID:
18196204
37.

Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.

Twardowski PW, Smith-Powell L, Carroll M, VanBalgooy J, Ruel C, Frankel P, Synold TW.

Cancer Invest. 2008 Feb;26(1):53-9. doi: 10.1080/07357900701681541.

PMID:
18181046
38.

Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.

Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, Pond GR, Johnson C, Colevas AD, Synold TW, Vasist LS, Winquist E.

Invest New Drugs. 2008 Jun;26(3):257-64. Epub 2007 Nov 24.

PMID:
18038218
39.

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

Lee CW, BĂ©langer K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L.

Invest New Drugs. 2008 Jun;26(3):249-55. Epub 2007 Oct 26.

PMID:
17962907
40.

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ.

Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8. Epub 2007 Sep 26.

PMID:
17899082
41.

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.

Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL.

Clin Cancer Res. 2007 Aug 15;13(16):4832-9.

42.

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.

Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P; National Cancer Institute Organ Dysfunction Working Group.

Clin Cancer Res. 2007 Jun 15;13(12):3660-6.

43.

Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.

Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR.

J Cancer Res Clin Oncol. 2007 Oct;133(10):705-11. Epub 2007 May 17.

PMID:
17508219
44.

Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.

Morgan RJ Jr, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):373-8.

PMID:
17362315
45.

Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.

Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH.

Clin Cancer Res. 2007 Feb 15;13(4):1232-7.

46.

Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer.

Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW.

Pharmacogenomics J. 2007 Oct;7(5):362-5. Epub 2007 Jan 16.

PMID:
17224914
47.

DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene.

Besaratinia A, Synold TW, Chen HH, Chang C, Xi B, Riggs AD, Pfeifer GP.

Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10058-63. Epub 2005 Jul 11.

48.
49.

A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.

Shibata SI, Pezner R, Chu D, Doroshow JH, Chow WA, Leong LA, Margolin KA, McNamara MV, Morgan RJ Jr, Raschko JW, Somlo G, Tetef ML, Yen Y, Synold TW, Wagman L, Vora N, Carroll M, Lin S, Longmate J.

Eur J Surg Oncol. 2004 Aug;30(6):650-7.

PMID:
15256240
50.

Supplemental Content

Loading ...
Support Center